Fast-Fail Trial Shows New Approach to Identifying Brain Targets for Clinical Treatments

A first-of-its-kind trial has demonstrated that a receptor involved in the brain’s reward system may be a viable target for treating anhedonia (or lack of pleasure), a key symptom of several mood and anxiety disorders. The results of this innovative fast-fail trial, funded by the National Institute of Mental Health (NIMH), are published in Nature Medicine.